MARKET

AVXL

AVXL

Anavex Life Scie
NASDAQ
9.10
0.00
0.00%
Opening 14:37 06/02 EDT
OPEN
9.17
PREV CLOSE
9.10
HIGH
9.19
LOW
8.92
VOLUME
489.90K
TURNOVER
2.68M
52 WEEK HIGH
15.24
52 WEEK LOW
7.36
MARKET CAP
735.62M
P/E (TTM)
-13.4456
1D
5D
1M
3M
1Y
5Y
Anavex gains compositions patent for Alzheimer's drug candidate
Seeking Alpha · 1d ago
ANAVEX Secures New US Intellectual Property Compositions Patent For ANAVEX2-73 (blarcamesine)
Benzinga · 1d ago
BRIEF-Anavex Announces Issuance Of New U.S. Intellectual Property Compositions Patent For Anavex®2-73 (Blarcamesine)
Reuters · 1d ago
Anavex Life Sciences Gets New Patent for Expanded Coverage of Anavex 2-73
Anavex Life Sciences Gets New Patent for Expanded Coverage of Anavex 2-73
MT Newswires · 1d ago
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet
NASDAQ · 2d ago
Unusual Call Option Trade in Anavex Life Sciences (AVXL) Worth $160.97K
NASDAQ · 6d ago
Anavex Life Scie: Current report
Press release · 05/24 22:00
Cassava Sciences' Simufilam, Anavex's Blarcamesine, And Aricept: Shared Mechanisms Of Action In The Treatment Of Alzheimer's Disease
Seeking Alpha · 05/16 18:56
More
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066, a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer.

Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.